New Technology Provides Advanced Patient
Positioning Capabilities With the Radixact System, Making it Easier
to Deliver Fast and Effective Radiotherapy Treatments
MADISON,
Wis. and DAYTONA BEACH,
Fla., Aug. 13, 2024 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) and Halifax Health, in Volusia County, Florida, announced today that
the Charles L. and Miki N. Grant Cancer Center for Hope medical
team is the first in the U.S. to treat cancer patients using the
Accuray Radixact® System with VitalHold™* technology.
The new VitalHold feature will provide a resource for effectively
positioning the patient and monitoring the accuracy of that
positioning throughout their treatment, enhancing precision in
radiation delivery. The new system is housed at the Cancer Center
for Hope – Port Orange.
Halifax Health augmented its Radixact System with the Accuray
proprietary ClearRT® helical CT imaging
and Synchrony® real-time adaptive delivery
technologies. The comprehensive radiotherapy delivery system, in
combination with VitalHold, is designed to facilitate treatment of
a wider range of cancer cases including breast cancer, faster and
with less harm to patients.
"With the estimated number of new cancer cases in the U.S.
anticipated to increase by about 35% between the year 2022 and
20401, it's important that medical teams have the
resources they need to offer the best possible care today and into
the future. The Radixact System is designed to offer certainty in
every step of the treatment process, from simulation through
radiation delivery, to facilitate high quality cancer care today
while also providing a platform able to evolve with continued
innovation," said Suzanne Winter,
president and CEO of Accuray.
Ms. Winter continued, "We are proud to partner with the Halifax
Health team as they continue to advance patient centered cancer
care in Volusia County. Their
treatment of the first patients in the U.S. using VitalHold on the
Radixact System shows their dedication to investing in options for
care that have the potential to meaningfully improve the lives of
their patients."
The VitalHold feature incorporates a fully integrated and
automated surface-guided radiotherapy (SGRT) solution, Catalyst+ HD
from C-RAD, on the Radixact System that offers multiple benefits
for medical teams and their patients. SGRT is a technology that
supports highly accurate positioning by scanning a patient's body
surface with a high-resolution camera and reconstructing it as a 3D
image in real-time. The reconstructed image enables clinicians to
easily visualize the difference between the current body position
and the target position, helping to ensure high reproducibility of
the patient position during treatment.
In addition, VitalHold enables deep inspiration breath hold
(DIBH) treatments on the Radixact System. During DIBH treatments, a
patient takes a deep breath which moves the heart away from the
chest wall and the targeted tumor to help minimize radiation dose
to organs at risk (OARs) and reduce associated complications later
in life. VitalHold DIBH treatments use SGRT to confirm the patient
is appropriately positioned to deliver radiation. SGRT supports
tattoo-free positioning, meaning no permanent markers are needed on
the patient's skin to align the patient before radiation treatment
delivery. Tattoo-free treatments increase patient comfort and
potentially improve cosmetic results.
"As the first and only center in the U.S. to treat cancer using
the Radixact System and VitalHold, we are demonstrating our
commitment to providing the highest level of care to the people in
our community," said Jeff Feasel,
President and CEO of Halifax Health. "The full-featured
Radixact® System provides us with the tools we need to
think differently about how we use radiation therapy within our
practice. Moving forward, we will continue to lengthen and
improve the quality of patients' lives, making it possible to
eliminate some of the fear associated with a cancer diagnosis."
"We are delighted that the VitalHold solution has been chosen by
the Halifax Health team. Equipping their Radixact®
System with SGRT will support in serving the Volusia county community with cutting-edge
cancer care. VitalHold™ is a powerful ally in enhancing precision
in radiation delivery, providing advanced patient positioning
capabilities. We are honored that the first patient has
successfully been treated and congratulate Halifax Health team on
this milestone," said Cecilia de
Leeuw, CEO of C-RAD.
About Halifax Health
Recognized as one of the 50 Top Cardiovascular Hospitals™ in
the United States by IBM Watson
Health™, Halifax Health serves Volusia and Flagler counties, providing a continuum of
health care services through a network of organizations including a
tertiary hospital, two community hospitals, an urgent care network,
psychiatric services, a cancer treatment center with five outreach
locations, the area's largest hospice, a center for inpatient
rehabilitation, outpatient rehabilitation clinics, primary care
walk-in clinics, a clinic specializing in women's health, a
pediatric care community clinic, three children's medical
practices, a home health care agency and an exclusive provider
organization. Halifax Health offers the area's only Level II Trauma
Center, Center for Transplant Services, Pediatric Intensive Care
Unit, Pediatric Emergency Department with board-certified
pediatricians on staff 24/7, Child and Adolescent Behavioral
Services, OB Emergency Department and Level III Neonatal Intensive
Care Unit that cares for babies born earlier than 28 weeks. It's
also the area's longest-standing Thrombectomy-Capable Stroke Center
(TSC) offering complete Neurosurgical Services. For more
information, visit halifaxhealth.org
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions designed to deliver radiation
treatments for even the most complex cases—while making commonly
treatable cases even easier—to meet the full spectrum of patient
needs. We are dedicated to continuous innovation in radiation
therapy for oncology, neuro-radiosurgery, and beyond, as we partner
with clinicians and administrators, empowering them to help
patients get back to their lives, faster. Accuray is headquartered
in Madison, Wisconsin, with
facilities worldwide. To learn more, visit www.accuray.com or
follow us on Facebook, LinkedIn, X, and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited to, expectations regarding the
company's products and upgrades, market expectations, clinical
applications, clinical results, patient experiences and patient
outcomes. These forward-looking statements involve risks and
uncertainties. If any of these risks or uncertainties
materialize, or if any of the company's assumptions prove
incorrect, actual results could differ materially from the results
expressed or implied by these forward-looking statements. These
risks and uncertainties include, but are not limited to, the
company's ability to achieve widespread market acceptance of its
products, including new product innovations and releases; the
company's ability to develop new products or improve existing
products to meet customers' needs; the company's ability to
anticipate or keep pace with changes in the marketplace; and the
direction of technological innovation and customer demands and such
other risks identified under the heading "Risk Factors" in the
company's quarterly report on Form 10-Q, filed with the Securities
and Exchange Commission (the "SEC") on May
8, 2024, and as updated periodically with the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
John Guthrie
Vice President of Corporate Communications, Halifax Health
(386) 425-4372
john.guthrie@halifax.org
*VitalHold™ availability is subject to regulatory clearance or
approval in some markets.
1 International Agency for Research on Cancer.
https://gco.iarc.fr/tomorrow/en/dataviz/bubbles?populations=840.
Accessed on July 23, 2024.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halifax-health-in-florida-is-first-in-the-us-to-treat-patients-with-cancer-using-the-accuray-radixact-radiation-delivery-system-and-vitalhold-technology-302220799.html
SOURCE Accuray Incorporated